×
About 79,502 results

ALLMedicine™ Hepatitis B Center

Research & Reviews  38,123 results

Systemic immune-inflammation index predicts postoperative acute kidney injury in hepato...
https://doi.org/10.1097/MD.0000000000025335
Medicine Xu J, Hu S et. al.

Apr 9th, 2021 - The systemic immune-inflammation index (SII) is an independent prognostic predictor of hepatocellular carcinoma (HCC). The present investigation examined whether an association exists between preoperative SII value and postoperative acute kidney i...

HLA-DPB1 alleles in hepatitis B vaccine response: A meta-analysis.
https://doi.org/10.1097/MD.0000000000024904
Medicine Ou G, Liu X et. al.

Apr 9th, 2021 - The role of the HLA-DRB1 and HLA-DQB1 genes in the antibody response to hepatitis B (HB) vaccine has been well established; however, the involvement of the HLA-DPB1 allele in the HB vaccine immune response remained to be clarified by a systematic ...

Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis ...
https://doi.org/10.14309/ajg.0000000000001176
The American Journal of Gastroenterology; Tan HK, Teng MLP et. al.

Apr 9th, 2021 - Decompensation with ascites portends a poor prognosis in cirrhosis. The aim of this study was to compare the outcomes of patients with nonalcoholic steatohepatitis (NASH) with hepatitis B virus (HBV) cirrhosis after decompensation with ascites. We...

Risk factors of dengue fever in an urban area in Vietnam: a case-control study.
https://doi.org/10.1186/s12889-021-10687-y 10.1038/nature12060 10.1186/s12879-017-2326-8 10.3402/gha.v6i0.18632 10.1002/0471445428 10.1016/j.apjtm.2015.06.009 10.5365/wpsar.2010.1.1.011 10.3389/fcimb.2017.00317 10.4269/ajtmh.2012.12-0315
BMC Public Health; Nguyen-Tien T, Do DC et. al.

Apr 8th, 2021 - Dengue is a mosquito-borne flavivirus present in many metropolitan cities of tropical countries. During and after the dengue season (September 2018 to January 2019), we conducted a case-control study in order to determine the risk factors for deng...

Monocyte dysregulation: consequences for hepatic infections.
https://doi.org/10.1007/s00281-021-00852-1 10.1038/nrgastro.2015.200 10.1038/nrgastro.2016.168 10.1146/annurev-immunol-051116-052415 10.1016/j.jhep.2013.12.025 10.1016/j.chom.2016.06.002 10.1038/ni.2691 10.1038/s41419-018-0377-4 10.1038/cti.2016.62 10.1038/ncomms10321 10.1038/nri.2017.28 10.1038/ni1309 10.1038/nri3070 10.1556/EuJMI.2.2012.2.1 10.1016/j.immuni.2016.02.015 10.1016/j.immuni.2017.04.018 10.1016/j.immuni.2018.10.005 10.1146/annurev.immunol.021908.132557 10.1016/S1074-7613(03)00174-2 10.3389/fimmu.2020.01117 10.1128/MCB.20.11.4106-4114.2000 10.3389/fcimb.2013.00032 10.1146/annurev.immunol.20.083001.084359 10.1182/blood-2010-02-258558 10.1084/jem.20141539 10.1182/blood-2009-07-235028 10.1038/s41590-020-0661-1 10.1172/JCI29919 10.4049/jimmunol.180.10.6846 10.1186/s12879-014-0621-1 10.1172/JCI119798 10.1073/pnas.94.22.12053 10.1016/S1074-7613(03)00171-7 10.1073/pnas.131207398 10.1016/j.immuni.2008.05.019 10.1128/IAI.01314-06 10.1182/blood-2009-04-217489 10.1186/1742-2094-9-270 10.1371/journal.ppat.1001045 10.1371/journal.ppat.1003096 10.4049/jimmunol.1701543 10.4049/jimmunol.1601896 10.1038/s41577-020-0331-4 10.1161/ATVBAHA.108.173898 10.1038/sj.jhh.1001990 10.3389/fimmu.2018.02948 10.1111/j.1365-3024.2005.00754.x 10.1038/s41467-020-17260-y 10.1016/j.immuni.2014.06.008 10.1016/j.immuni.2014.01.006 10.1136/gutjnl-2019-318382 10.1038/ni.2705 10.1155/2012/949157 10.3389/fimmu.2019.02852 10.1002/hep.29544 10.1016/j.cld.2010.09.002 10.1093/ofid/ofy161 10.1016/j.micinf.2012.05.013 10.4269/ajtmh.2002.66.578 10.1111/j.1365-3024.2003.00662.x 10.1128/IAI.74.1.118-124.2006 10.1016/j.jhep.2016.01.013 10.4049/jimmunol.175.2.788 10.1128/IAI.00589-12 10.1128/CVI.00129-08 10.1096/fj.03-0578fje 10.1073/pnas.92.26.12175 10.1371/journal.ppat.1000434 10.1002/hep.24457 10.1016/j.jhep.2004.11.008 10.1007/s10456-014-9454-1 10.1128/IAI.00798-10 10.1093/eurheartj/ehy085 10.4049/jimmunol.1700129 10.1189/jlb.1206735 10.1042/bj3301217 10.1111/j.0141-9838.2004.00669.x 10.1073/pnas.1119964109 10.1016/B978-0-12-407679-2.00005-3 10.1038/s41598-017-14935-3 10.4049/jimmunol.177.1.22 10.4049/jimmunol.1501046 10.1093/infdis/jiu439 10.1016/j.jid.2017.11.029 10.1155/2019/4103819 10.1016/j.imbio.2009.06.010 10.1371/journal.ppat.1004414 10.4049/jimmunol.182.2.1107 10.1016/S0140-6736(13)61949-2 10.1371/journal.ppat.1004282 10.3389/fmicb.2020.01973 10.3389/fimmu.2018.01970 10.1038/s41598-019-42703-y 10.1006/expr.1997.4148 10.1111/pim.12282 10.1186/s13071-016-1350-7 10.1128/IAI.00472-09 10.1038/nm.3189 10.1371/journal.ppat.1004203 10.1084/jem.20090900 10.1084/jem.20160334 10.1172/JCI127286 10.1371/journal.ppat.1007847 10.1128/JVI.78.22.12647-12656.2004 10.1038/s41467-020-16849-7 10.1111/imm.13011 10.1056/NEJMra031087 10.1084/jem.194.10.1395 10.1038/nri.2016.69 10.1016/j.jhep.2016.01.026 10.4049/jimmunol.1800848 10.1016/j.jhep.2016.01.028 10.1371/journal.pone.0097006 10.1371/journal.pone.0017484 10.1093/infdis/jiu599 10.1016/j.jhep.2017.04.023 10.1016/j.jhepr.2019.11.006 10.4049/jimmunol.1201625 10.1046/j.1365-2567.2003.01699.x 10.1002/hep.21482 10.1016/j.jcmgh.2015.12.005 10.1136/gut.46.2.260 10.1053/j.gastro.2009.09.009 10.4049/jimmunol.1002006 10.1016/j.jhep.2017.02.026 10.3390/v4112650 10.1128/JVI.03733-14
Seminars in Immunopathology; Sellau J, Puengel T et. al.

Apr 8th, 2021 - Liver disorders due to infections are a substantial health concern in underdeveloped and industrialized countries. This includes not only hepatotropic viruses (e.g., hepatitis B, hepatitis C) but also bacterial and parasitic infections such as ame...

see more →

Guidelines  147 results

Hepatocellular carcinoma
https://www.nature.com/articles/s41572-020-00240-3
Nature Reviews; Llovet JM

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepa...

Chemical Risk Factors of Primary Liver Cancer: An Update
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801911/
Hepatic Medicine: Evidence and Research; Barsouk A, Thandra KC et. al.

Jan 4th, 2021 - Primary liver cancer has the sixth highest incidence and fourth highest cancer mortality worldwide. Hepatitis B is the leading cause of liver cancer, though its incidence is decreasing with vaccination. Alcohol is the leading cause of liver transp...

Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Serv...
https://doi.org/10.1001/jama.2020.22980
JAMA , Krist AH et. al.

Dec 15th, 2020 - An estimated 862 000 persons in the US are living with chronic infection with hepatitis B virus (HBV). Persons born in regions with a prevalence of HBV infection of 2% or greater, such as countries in Africa and Asia, the Pacific Islands, and part...

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: A...
https://doi.org/10.1200/JCO.20.01757
Journal of Clinical Oncology : Official Journal of the Am... Hwang JP, Feld JJ et. al.

Jul 27th, 2020 - This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management. All patients anticipating systemic anticancer therapy should be tested for HBV by 3 tests-hepatitis B surface an...

Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update
https://ascopubs.org/doi/full/10.1200/JCO.20.01757
Journal of Clinical Oncology; Hwang JP

Jul 26th, 2020 - This Provisional Clinical Opinion update presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management.

see more →

Drugs  247 results see all →

Clinicaltrials.gov  39,447 results

Systemic immune-inflammation index predicts postoperative acute kidney injury in hepato...
https://doi.org/10.1097/MD.0000000000025335
Medicine Xu J, Hu S et. al.

Apr 9th, 2021 - The systemic immune-inflammation index (SII) is an independent prognostic predictor of hepatocellular carcinoma (HCC). The present investigation examined whether an association exists between preoperative SII value and postoperative acute kidney i...

HLA-DPB1 alleles in hepatitis B vaccine response: A meta-analysis.
https://doi.org/10.1097/MD.0000000000024904
Medicine Ou G, Liu X et. al.

Apr 9th, 2021 - The role of the HLA-DRB1 and HLA-DQB1 genes in the antibody response to hepatitis B (HB) vaccine has been well established; however, the involvement of the HLA-DPB1 allele in the HB vaccine immune response remained to be clarified by a systematic ...

Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis ...
https://doi.org/10.14309/ajg.0000000000001176
The American Journal of Gastroenterology; Tan HK, Teng MLP et. al.

Apr 9th, 2021 - Decompensation with ascites portends a poor prognosis in cirrhosis. The aim of this study was to compare the outcomes of patients with nonalcoholic steatohepatitis (NASH) with hepatitis B virus (HBV) cirrhosis after decompensation with ascites. We...

Risk factors of dengue fever in an urban area in Vietnam: a case-control study.
https://doi.org/10.1186/s12889-021-10687-y 10.1038/nature12060 10.1186/s12879-017-2326-8 10.3402/gha.v6i0.18632 10.1002/0471445428 10.1016/j.apjtm.2015.06.009 10.5365/wpsar.2010.1.1.011 10.3389/fcimb.2017.00317 10.4269/ajtmh.2012.12-0315
BMC Public Health; Nguyen-Tien T, Do DC et. al.

Apr 8th, 2021 - Dengue is a mosquito-borne flavivirus present in many metropolitan cities of tropical countries. During and after the dengue season (September 2018 to January 2019), we conducted a case-control study in order to determine the risk factors for deng...

Monocyte dysregulation: consequences for hepatic infections.
https://doi.org/10.1007/s00281-021-00852-1 10.1038/nrgastro.2015.200 10.1038/nrgastro.2016.168 10.1146/annurev-immunol-051116-052415 10.1016/j.jhep.2013.12.025 10.1016/j.chom.2016.06.002 10.1038/ni.2691 10.1038/s41419-018-0377-4 10.1038/cti.2016.62 10.1038/ncomms10321 10.1038/nri.2017.28 10.1038/ni1309 10.1038/nri3070 10.1556/EuJMI.2.2012.2.1 10.1016/j.immuni.2016.02.015 10.1016/j.immuni.2017.04.018 10.1016/j.immuni.2018.10.005 10.1146/annurev.immunol.021908.132557 10.1016/S1074-7613(03)00174-2 10.3389/fimmu.2020.01117 10.1128/MCB.20.11.4106-4114.2000 10.3389/fcimb.2013.00032 10.1146/annurev.immunol.20.083001.084359 10.1182/blood-2010-02-258558 10.1084/jem.20141539 10.1182/blood-2009-07-235028 10.1038/s41590-020-0661-1 10.1172/JCI29919 10.4049/jimmunol.180.10.6846 10.1186/s12879-014-0621-1 10.1172/JCI119798 10.1073/pnas.94.22.12053 10.1016/S1074-7613(03)00171-7 10.1073/pnas.131207398 10.1016/j.immuni.2008.05.019 10.1128/IAI.01314-06 10.1182/blood-2009-04-217489 10.1186/1742-2094-9-270 10.1371/journal.ppat.1001045 10.1371/journal.ppat.1003096 10.4049/jimmunol.1701543 10.4049/jimmunol.1601896 10.1038/s41577-020-0331-4 10.1161/ATVBAHA.108.173898 10.1038/sj.jhh.1001990 10.3389/fimmu.2018.02948 10.1111/j.1365-3024.2005.00754.x 10.1038/s41467-020-17260-y 10.1016/j.immuni.2014.06.008 10.1016/j.immuni.2014.01.006 10.1136/gutjnl-2019-318382 10.1038/ni.2705 10.1155/2012/949157 10.3389/fimmu.2019.02852 10.1002/hep.29544 10.1016/j.cld.2010.09.002 10.1093/ofid/ofy161 10.1016/j.micinf.2012.05.013 10.4269/ajtmh.2002.66.578 10.1111/j.1365-3024.2003.00662.x 10.1128/IAI.74.1.118-124.2006 10.1016/j.jhep.2016.01.013 10.4049/jimmunol.175.2.788 10.1128/IAI.00589-12 10.1128/CVI.00129-08 10.1096/fj.03-0578fje 10.1073/pnas.92.26.12175 10.1371/journal.ppat.1000434 10.1002/hep.24457 10.1016/j.jhep.2004.11.008 10.1007/s10456-014-9454-1 10.1128/IAI.00798-10 10.1093/eurheartj/ehy085 10.4049/jimmunol.1700129 10.1189/jlb.1206735 10.1042/bj3301217 10.1111/j.0141-9838.2004.00669.x 10.1073/pnas.1119964109 10.1016/B978-0-12-407679-2.00005-3 10.1038/s41598-017-14935-3 10.4049/jimmunol.177.1.22 10.4049/jimmunol.1501046 10.1093/infdis/jiu439 10.1016/j.jid.2017.11.029 10.1155/2019/4103819 10.1016/j.imbio.2009.06.010 10.1371/journal.ppat.1004414 10.4049/jimmunol.182.2.1107 10.1016/S0140-6736(13)61949-2 10.1371/journal.ppat.1004282 10.3389/fmicb.2020.01973 10.3389/fimmu.2018.01970 10.1038/s41598-019-42703-y 10.1006/expr.1997.4148 10.1111/pim.12282 10.1186/s13071-016-1350-7 10.1128/IAI.00472-09 10.1038/nm.3189 10.1371/journal.ppat.1004203 10.1084/jem.20090900 10.1084/jem.20160334 10.1172/JCI127286 10.1371/journal.ppat.1007847 10.1128/JVI.78.22.12647-12656.2004 10.1038/s41467-020-16849-7 10.1111/imm.13011 10.1056/NEJMra031087 10.1084/jem.194.10.1395 10.1038/nri.2016.69 10.1016/j.jhep.2016.01.026 10.4049/jimmunol.1800848 10.1016/j.jhep.2016.01.028 10.1371/journal.pone.0097006 10.1371/journal.pone.0017484 10.1093/infdis/jiu599 10.1016/j.jhep.2017.04.023 10.1016/j.jhepr.2019.11.006 10.4049/jimmunol.1201625 10.1046/j.1365-2567.2003.01699.x 10.1002/hep.21482 10.1016/j.jcmgh.2015.12.005 10.1136/gut.46.2.260 10.1053/j.gastro.2009.09.009 10.4049/jimmunol.1002006 10.1016/j.jhep.2017.02.026 10.3390/v4112650 10.1128/JVI.03733-14
Seminars in Immunopathology; Sellau J, Puengel T et. al.

Apr 8th, 2021 - Liver disorders due to infections are a substantial health concern in underdeveloped and industrialized countries. This includes not only hepatotropic viruses (e.g., hepatitis B, hepatitis C) but also bacterial and parasitic infections such as ame...

see more →

News  1,507 results

Treatment Paradigm for Chronic HBV in Flux
https://www.medscape.com/viewarticle/948611

Apr 1st, 2021 - These days deciding when to stop targeted treatment for chronic hepatitis B is a bigger challenge than knowing when to start, Norah A. Terrault, MD, MPH, observed at the Gastroenterology Updates, IBD, Liver Disease Conference. That's because the t...

Progress and Challenges in US Perinatal HBV Prevention Program
https://www.medscape.com/viewarticle/945121

Feb 2nd, 2021 - NEW YORK (Reuters Health) - The United States has made progress in identifying infants born to hepatitis B surface antigen (HBsAg)-positive women and getting them vaccinated. Yet, there is also substantial room for improvement, including closing t...

Hepatocellular carcinoma
https://www.nature.com/articles/s41572-020-00240-3
Nature Reviews; Llovet JM

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepa...

Eliminating Hepatitis by 2030: HHS Releases New Strategic Plan
https://www.medscape.com/viewarticle/944180

Jan 14th, 2021 - In an effort to counteract alarming trends in rising hepatitis infections, the U.S. Department of Health and Human Services has developed and released its Viral Hepatitis National Strategic Plan 2021-2025, which aims to eliminate viral hepatitis i...

Chemical Risk Factors of Primary Liver Cancer: An Update
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801911/
Hepatic Medicine: Evidence and Research; Barsouk A, Thandra KC et. al.

Jan 4th, 2021 - Primary liver cancer has the sixth highest incidence and fourth highest cancer mortality worldwide. Hepatitis B is the leading cause of liver cancer, though its incidence is decreasing with vaccination. Alcohol is the leading cause of liver transp...

see more →

Patient Education  31 results see all →